Japan Cord Blood Banking Market to Grow with a CAGR of 4.41% through 2031
Increased Awareness of Stem Cell
Therapies and Rising Incidence of Genetic and Autoimmune Disorders are expected to drive the Japan Cord Blood Banking Market growth in
the forecast period, 2027-2031
According to
TechSci Research report, “Japan Cord Blood Banking Market – By Region,
Competition, Forecast & Opportunities, 2031F”, the Japan Cord Blood
Banking Market stood at USD 21.91 Million in 2025 and is anticipated to grow
with a CAGR of 4.41% in the forecast period, 2027-2031.
Japan’s
demographic landscape is undergoing a profound transformation, with over 28% of
its population aged 65 and above. This aging trend is directly correlated with
a surge in chronic and degenerative conditions such as leukemia, lymphoma,
anemia, diabetes, and neurodegenerative diseases. Many of these conditions are
now being addressed through hematopoietic stem cell therapies sourced from cord
blood. Consequently, families particularly those with a history of such
diseases are increasingly viewing cord blood banking as a proactive health
asset, fueling demand for long-term storage solutions.
Japan has
emerged as a frontrunner in regenerative medicine, supported by high R&D
intensity, translational research initiatives, and cross-sector collaboration.
Cord blood, enriched with hematopoietic stem cells, is central to ongoing
breakthroughs in treatments for autoimmune disorders, inherited metabolic
conditions, and emerging solid tumor therapies. The expanding clinical pipeline
and positive trial outcomes are materially increasing the clinical utility and
perceived ROI of cord blood storage, thereby accelerating adoption among both
healthcare providers and consumers.
The Japanese
government has enacted targeted regulatory frameworks that actively support the
growth of cord blood banking and regenerative therapies. The Act on the Safety
of Regenerative Medicine and the Pharmaceuticals and Medical Devices Act (PMDA)
not only streamline approval processes but also provide structured oversight
for safety and ethical compliance. These policies have significantly reduced
market entry barriers for private operators and enhanced investor confidence in
the sector. Additionally, the government’s push for clinical-grade biobanking
infrastructure has catalyzed partnerships between hospitals, research
institutions, and cord blood banks further reinforcing the market’s upward
trajectory.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Japan
Cord Blood Banking Market”
The Japan Cord
Blood Banking Market is segmented into sector, service, component, application,
end user, modality, device architecture, end users, regional distribution, and
company.
Based on its application,
the Cancer
segment has emerged as the predominant market leader, Cord blood is a rich
source of hematopoietic stem cells, which are vital for reconstituting the
blood and immune systems following high-dose chemotherapy or radiation. This
makes cord blood transplantation a well-established treatment for various
blood-related cancers such as leukemia, lymphoma, and myelodysplastic
syndromes. In Japan, these conditions represent a significant portion of
oncology cases treated with stem cell transplants, reinforcing the dominance of
the cancer segment in cord blood banking.
Japan has one of
the highest cancer incidence rates among developed countries, driven by an
aging population, lifestyle changes, and improved diagnostic practices.
According to national health statistics, cancers like leukemia and lymphoma are
not only prevalent but also increasingly being detected at stages where stem
cell transplantation is a viable treatment option. This trend significantly
boosts demand for accessible and high-quality cord blood units. Stem cell
transplantation, including the use of cord blood, is an integral part of
Japan’s oncology treatment ecosystem, supported by both public healthcare
systems and private institutions. National treatment guidelines from the
Japanese Society of Hematology and other professional bodies advocate for the
use of cord blood transplants in eligible cancer patients, thus
institutionalizing demand for cord blood banking services.
Based on its end
user, the Pharmaceutical
& Biotechnology Companies segment has emerged as the predominant market leader,
Pharmaceutical and biotech companies in Japan are increasingly focusing on
regenerative medicine and cell therapy development, areas where cord
blood-derived hematopoietic and mesenchymal stem cells (HSCs and MSCs) are
critical raw materials. These companies rely on cord blood banks for
consistent, high-quality, ethically sourced stem cells that are essential for
developing treatments targeting oncology, autoimmune diseases, rare genetic
conditions, and degenerative disorders. By partnering with cord blood banks or
establishing proprietary storage and sourcing agreements, these companies
secure a reliable supply chain of clinically viable cells for R&D,
early-stage trials, and advanced therapeutic product pipelines.
Japan’s pharma
and biotech sectors are deeply invested in stem cell-based preclinical and
clinical studies. Cord blood provides a valuable cellular model for drug
efficacy testing, disease modeling, and safety profiling particularly in
hematological, metabolic, and neurological disorders. As the volume and
complexity of clinical trials increase, demand from pharmaceutical firms for
access to high-quality, banked cord blood samples continues to rise, further
solidifying their leading position as end users.
Major companies
operating in Japan Cord Blood Banking Market are:
·
StemCell Institute
·
NPO Hyogo Cord Blood Bank
·
Central Cord Blood Bank
·
Japan Red Cross Society
Download
Free Sample Report
Customers can
also request for 10% free customization on this report
“The Japan Cord
Blood Banking Service Market is poised for sustained growth, driven by the
country’s aging population, advancements in regenerative medicine, and strong
government backing for stem cell research and innovation. As demand accelerates
from pharmaceutical and biotech companies, alongside rising consumer awareness
of personalized healthcare, the market is evolving from a niche service into a
strategic pillar of Japan’s biomedical landscape. Continued investment in
biobanking infrastructure, clinical applications, and public-private
collaborations will further solidify Japan’s position as a key player in the
global cord blood banking ecosystem.,” said Mr. Karan Chechi, Research Director
of TechSci Research, a research-based management consulting firm.
“Japan Cord Blood Banking Market, By Sector (Private Cord Blood Banks, Public Cord Blood
Banks, PPP Cord Blood Banks), By Service (Preservation & Storage, Processing,
Collection & Transportation, Analysis), By Component (Cord Blood, Cord
Tissue), By Application (Cancer, Blood Disorders, Immune Disorders, Diabetes,
Metabolic Disorders, Others), By End User (Pharma & Biotech Companies, Hospitals
& Specialty Clinics, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F”,
has evaluated the future growth potential of Japan Cord Blood Banking Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Japan Cord Blood Banking Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com